A 25x-NBOMe compound is a highly potent synthetic phenethylamine hallucinogen built on a 2,5-dimethoxyphenethylamine core that carries an N-(2-methoxybenzyl) group on the nitrogen.[1] Membership is defined by that rigid structural template — the same nitrogen substituent and the same aromatic scaffold — with a single letter in the "25x" prefix encoding the variable 4-position substituent.
The class spans six members on Psychedex: 25B-NBOMe, 25C-NBOMe, 25D-NBOMe, 25E-NBOMe, 25I-NBOMe, and 25N-NBOMe. The 4-position substituent — bromo, chloro, methyl, ethyl, iodo, or nitro — is the only structural variable, and the members converge on the same receptor pharmacology and the same broad effect profile.
These compounds emerged from academic work on the structure of the 5-HT2A receptor and reached illicit markets around 2010–2012, most often distributed on blotter paper sold under names such as "N-Bomb" or "Smiles".[1] Active in microgram quantities, they produce visual hallucinations, perceptual distortion, and sympathomimetic somatic effects across their hallucinogenic range, with confusion, agitation, and severe medical toxicity at higher exposures.[2]
Pharmacology
The members of the class converge on a single molecular endpoint — high-affinity full agonism at the serotonin 5-HT2A receptor — through a shared structural motif rather than through chemically distinct routes.[1][3]
The N-(2-methoxybenzyl) group that defines the class makes contact with residues in the 5-HT2A binding pocket that the parent 2C phenethylamine nitrogen reaches less efficiently, producing the large potency gain that separates NBOMe compounds from their precursors.[1]
| Receptor target | Class-wide activity | Contribution to the effect and risk profile |
|---|---|---|
| 5-HT2A | Subnanomolar to low-nanomolar full agonism across members | Drives the hallucinogenic effects and the central pathway to seizures and serotonin toxicity[1] |
| 5-HT2C | High-affinity agonism, somewhat weaker than at 5-HT2A | Modulates cortical neurotransmitter release alongside 5-HT2A[4] |
| α1-adrenergic | Increased affinity relative to 2C parent compounds | Drives the sympathomimetic features — vasoconstriction, hypertension, tachycardia[3] |
| Histamine H1 | Increased affinity relative to 2C parent compounds | Minor somatic contribution[3] |
The mechanistic detail matters less for safety than the convergent endpoint: cortical 5-HT2A activation by an agonist with extreme binding affinity. Animal work on 25I-NBOMe has shown elevation of dopamine, serotonin, and glutamate in the frontal cortex, with blockade of either 5-HT2A or 5-HT2C attenuating the response — the neurochemical output of the class runs through both receptors but is anchored in 5-HT2A.[1]
The narrow receptor footprint matters too. NBOMe compounds show no meaningful monoamine reuptake inhibition and only weak 5-HT2B activity at pharmacologically relevant concentrations, which is why the toxidrome is predominantly serotonergic and sympathomimetic rather than mixed.[4][3]
Substances
The six members differ only at the aromatic 4-position; their pharmacological identity is otherwise uniform across the class.[4]
| Member | 4-position substituent | Role within the class |
|---|---|---|
| 25I-NBOMe | Iodo | The most extensively studied member and the dominant compound in forensic and clinical case literature[5] |
| 25C-NBOMe | Chloro | Well-characterized; implicated in documented fatalities[6] |
| 25B-NBOMe | Bromo | Well-characterized; involved in documented fatalities alongside 25I and 25C[5] |
| 25D-NBOMe | Methyl | Less commonly encountered on illicit markets; receptor pharmacology places it firmly within the class[4] |
| 25E-NBOMe | Ethyl | Less commonly encountered; quantitatively characterized as a high-affinity 5-HT2A agonist[4] |
| 25N-NBOMe | Nitro | Less commonly encountered; receptor profile comparable to the more circulated members[4] |
All members share the extreme potency that places the class in the microgram-dose range, and a bitter taste with sublingual oral numbness that harm-reduction literature has noted as distinguishing NBOMe blotters from LSD, which is typically tasteless.[1]
Subjective Effects
The class produces a serotonergic-psychedelic experience that broadens into confusion and agitation as exposure rises, accompanied throughout by sympathomimetic somatic features.[1][2]
| Exposure | Characteristic effects |
|---|---|
| Low | Euphoria, heightened sensory engagement, mild perceptual shifts, colour enhancement, and the early sympathomimetic signature of mydriasis and tachycardia |
| Moderate–high | Visual hallucinations including geometric patterns and complex imagery, altered sense of time, synesthesia, intensified somatic activation, and a rising likelihood of anxiety, confusion, or panic |
| High | Severe agitation, paranoia, loss of behavioural control, hypertension, hyperthermia, seizures, and progression toward the medical toxidrome described in the Safety section |
The same receptor activity drives both the psychedelic effects and the dangerous ones. Because the active range is in micrograms, the margin between a hallucinogenic dose and one that produces serious medical toxicity is unusually narrow across the class.[1][5] The sympathomimetic features — racing heart, raised temperature, sweating, vasoconstriction — appear inside the hallucinogenic range rather than emerging only at toxic exposures, which sets the class apart from most classical serotonergic psychedelics.[1]
Safety
Risk profile
The defining acute danger of this class is the narrow margin between a hallucinogenic exposure and a medically severe one. The compounds are active in microgram quantities and are distributed on blotter paper that a user cannot reliably dose-judge by inspection.They are frequently sold as LSD, so a person taking what they believe to be an LSD blotter may unknowingly consume an NBOMe at a dose well into its toxic range. Fatalities have been documented at the recreational exposure range, not only at intentionally high exposures.[1][5]
The clinical toxidrome is sympathomimetic with serotonergic features: tachycardia, hypertension, hyperthermia, mydriasis, diaphoresis, and severe agitation are the routine presentations, and seizures appear in a substantial share of severe intoxication cases.[1][5]
Rhabdomyolysis — skeletal muscle breakdown that carries a secondary risk of acute kidney injury — is documented across the case literature, and in severe overdose the picture can progress to the full serotonin-syndrome phenotype with multiorgan failure, metabolic acidosis, and disseminated intravascular coagulation.[1]
An "excited delirium" pattern — extreme agitation with hyperthermia and sympathetic overstimulation — has contributed to fatalities, including traumatic deaths driven by uncontrolled behaviour during the experience.[5] Forensic case series have analytically confirmed deaths involving 25I-NBOMe, 25C-NBOMe, and 25B-NBOMe, with victims clustering in their early twenties.[7][6][5]
There is no antidote. Clinical management is supportive — benzodiazepines for seizures and agitation, active cooling for hyperthermia, fluids and renal monitoring for rhabdomyolysis.[1][5] Combining an NBOMe with other serotonergic agents (MAOIs, MDMA, tryptamines) raises the risk of serotonin syndrome, and combining with stimulants compounds the hyperthermia and cardiovascular load.
Preclinical work has also identified neurotoxic signals beyond the acute toxidrome, including DNA damage and glial cell loss in cortical regions following repeated 25I-NBOMe exposure; the human significance at typical recreational exposures is not yet established.[8]
Tolerance & dependence
Functional tolerance develops rapidly with repeated use of 25x-NBOMe compounds, within days, driven by 5-HT2A receptor downregulation and desensitisation under sustained agonist exposure.[9][1] A seven-day exposure to 25I-NBOMe in rats reduced dopamine, serotonin, and glutamate responses to a subsequent challenge, with behavioural tolerance becoming evident from the third day; user-reported timelines align with that animal data.[9][1] Cross-tolerance is expected between members of the class and with classical 5-HT2A psychedelics such as LSD and psilocybin.
The class shows a dependence-liability signal that classical serotonergic psychedelics do not. Animal studies have demonstrated conditioned place preference and self-administration with NBOMe compounds, and chronic 25B-NBOMe exposure produces a dopaminergic remodelling pattern — D1 upregulation, D2 downregulation — that is associated with addictive drugs.[1]
The clinical significance for human users is not yet fully characterised, but the preclinical signal distinguishes the NBOMe class from its classical psychedelic relatives on this dimension. No physical withdrawal syndrome analogous to that of depressants or opioids has been characterised; compulsive-use patterns are plausible from the preclinical data and remain poorly studied in humans.
Recovery
There is no medication protocol specific to 25x-NBOMe dependence. Clinical recovery from problematic use draws on general substance-use frameworks — supportive counselling, relapse-prevention strategies, and treatment of any co-occurring conditions — and from the receptor side, 5-HT2A downregulation reverses once exposure stops, so the tolerance built during regular use is not permanent.A clinician or addiction-medicine service is the practical entry point for anyone struggling to reduce use, and any acute medical event during use is a medical emergency that warrants emergency-department care rather than a wait-and-see approach.
Recovery resources, crisis lines, and support pathways → View all
Members
references
- [1]
- [2]^abHalberstadt AL (2017) Pharmacology and Toxicology of N-Benzylphenethylamine (NBOMe) Hallucinogens — Current Topics in Behavioral Neurosciences doi:10.1007/7854_2016_64
- [3]
- [4]
- [5]
- [6]^abMorini L, Bernini M, Vezzoli S, Restori M, Moretti M, Crenna S, Papa P, Locatelli C, Osculati AMM, Vignali C, Groppi A (2017) Death after 25C-NBOMe and 25H-NBOMe consumption. — Forensic Science International doi:10.1016/j.forsciint.2017.08.028